Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Invest New Drugs ; 38(6): 1826-1835, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32535812

RESUMEN

We assessed the pharmacokinetics and safety of a single oral administration of selatinib to healthy Chinese subjects and evaluated the potential bioavailability advantage of selatinib relative to lapatinib. Healthy subjects aged 18-40 years were enrolled in this two-part study: Part 1, a single ascending dose (50-500 mg), randomized, double-blind, placebo-control study with 64 subjects; and Part 2, an open-label, positive control, randomized, three-treatment, three-period, three-sequence crossover design study, with 6 subjects administered a single 500-mg dose of selatinib tablets (A), selatinib suspension (B), or lapatinib tablets C) per cycle. In part 1, selatinib was well-tolerated up to the planned maximum dose of 500 mg; thus the maximum tolerated dose was not attained. Twenty-two adverse events were observed in 19 (36.5%) of the 52 subjects administered the test drug. The most common drug-related adverse event was diarrhea. The mean selatinib peak plasma concentration was 69.4-494 ng/mL, which was achieved in a median peak time of 3.5-4.5 h, with a mean elimination half-life between 13.8 and 15.8 h. In Part 2, A and B showed similar bioavailability. Plasma exposure to the active drug (selatinib plus the metabolite, lapatinib) after A intake was more than two-fold higher than that of the same dose of C. In the dose range of 50-500 mg, selatinib was safe and well-tolerated by healthy Chinese subjects, and it conformed with linear pharmacokinetics. Active exposure to selatinib was much greater than that to lapatinib, supporting its development as an adjuvant for anticancer treatment.


Asunto(s)
Compuestos de Anilina/administración & dosificación , Antineoplásicos/administración & dosificación , Quinazolinas/administración & dosificación , Receptor ErbB-2/antagonistas & inhibidores , Adolescente , Adulto , Compuestos de Anilina/efectos adversos , Compuestos de Anilina/sangre , Compuestos de Anilina/farmacocinética , Antineoplásicos/efectos adversos , Antineoplásicos/sangre , Antineoplásicos/farmacocinética , Disponibilidad Biológica , Estudios Cruzados , Método Doble Ciego , Receptores ErbB/antagonistas & inhibidores , Femenino , Voluntarios Sanos , Humanos , Lapatinib/metabolismo , Masculino , Quinazolinas/efectos adversos , Quinazolinas/sangre , Quinazolinas/farmacocinética , Equivalencia Terapéutica , Adulto Joven
2.
J Sep Sci ; 42(9): 1725-1732, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30839168

RESUMEN

Leonurus japonicus houtt, a well-known herb of traditional Chinese medicine, is widely used to treat gynaecological diseases. In this study, a rapid and sensitive liquid chromatography with tandem mass spectrometry method for simultaneously quantifying leonurine and stachydrine, the two main bioactive components in Leonurus japonicus houtt, was developed and validated. Plasma samples were prepared by protein precipitation with acetonitrile and separation by a Hewlett Packard XDB-C8 column (150 × 4.6 mm, id, 5 µm) equipped with a gradient elution system containing methanol-water and 0.1% formic acid at a flow-rate of 0.4 mL/min. Components were then detected by a mass spectrometer in positive electrospray ionization mode. This method showed good linearity, precision, accuracy, recovery, stability, and negligible matrix effects, which were within acceptable ranges. The method was successfully applied to compare the pharmacokinetics in normal rats and rats with cold-stagnation and blood-stasis primary dysmenorrhoea treated with Leonurus japonicus houtt electuary. The result showed significant differences (p < 0.05) in the pharmacokinetic parameters between the primary dysmenorrhoea and normal groups. This result implied that Leonurus japonicus houtt electuary remained longer and was absorbed slower in rats with primary dysmenorrhoea and exhibited higher bioavailability and peak concentration.


Asunto(s)
Medicamentos Herbarios Chinos/farmacocinética , Dismenorrea/tratamiento farmacológico , Ácido Gálico/análogos & derivados , Leonurus/química , Prolina/análogos & derivados , Animales , Medicamentos Herbarios Chinos/administración & dosificación , Dismenorrea/sangre , Femenino , Ácido Gálico/administración & dosificación , Ácido Gálico/farmacocinética , Humanos , Prolina/administración & dosificación , Prolina/farmacocinética , Ratas , Ratas Sprague-Dawley
3.
Environ Technol ; 39(12): 1607-1613, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28585470

RESUMEN

The present work investigates the properties of self-made magnetic filler from plastic waste bottle and explores a new technology approach of waste plastic resource utilization. The magnetic filler was prepared by air plasma modification and loading magnetic ferrite on the plastic strip from waste plastic bottle. The surface properties of magnetic filler were characterized by Atomic Force Microscope (AFM), contact angle system and Fourier Transform Infrared (FTIR). AFM images of original and modified plastic strip showed that low-temperature plasma treatment markedly increased the surface roughness of plastic strip. The mean roughness (Ra) of plastic strip rose from 1.116 to 5.024 nm. FTIR spectra indicated that a lot of polar oxygenic groups were introduced onto the surface of plastic by plasma modification. Modification by low-temperature plasma increased the hydrophilicity of plastic strip surface. When treatment time is 40 s, water contact angle of plastic strip surface reduced from 78.2° of original plastic strip to 25.3°. When used in bioreactor, magnetic filler had very favorable microenvironment for microorganism growth. Magnetic filler was more efficient for removing chemical oxygen demand (COD) and [Formula: see text] in sewage than nonmagnetic filler. The resource utilization of plastic wastes will become reality if the magnetic filler is applied widely.


Asunto(s)
Reactores Biológicos , Compuestos Férricos/química , Análisis de la Demanda Biológica de Oxígeno , Aguas del Alcantarillado , Propiedades de Superficie
4.
Int J Oncol ; 42(4): 1317-24, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23426981

RESUMEN

Dicer, a member of the RNase III family, is the key enzyme required for the biogenesis of microRNAs and small interfering RNAs. Recent evidence indicates that DICER1 expression levels vary among different solid tumors and decreased or increased DICER1 expression has been associated with aggressive cancers. In this study, we assessed DICER1 expression levels in acute myeloid leukemia (AML) and investigated its biological effects and transcriptional regulation in leukemia cell lines. We demonstrated that DICER1 was overexpressed in AML patients and leukemia cell lines by real-time quantitative PCR and western blot analysis. A functional assay demonstrated that the silencing of DICER1 inhibited cell proliferation and promoted apoptosis in leukemia cell lines. We also demonstrated that DICER1 was upregulated by the hematopoietic transcription factor, GATA1, through luciferase, electrophoretic mobility shift and chromatin immunoprecipitation assays. These data suggest that DICER1 plays an important role in AML and the finding that the upregulation of DICER1 is induced by GATA1 may provide a framework for the understanding of differential DICER1 expression levels in multiple types of cancer.


Asunto(s)
Apoptosis , Proliferación Celular , ARN Helicasas DEAD-box/genética , Factor de Transcripción GATA1/metabolismo , Leucemia Mieloide Aguda/metabolismo , Ribonucleasa III/genética , Secuencia de Bases , Estudios de Casos y Controles , ARN Helicasas DEAD-box/metabolismo , Factor de Transcripción GATA1/genética , Expresión Génica , Regulación Leucémica de la Expresión Génica , Técnicas de Silenciamiento del Gen , Humanos , Células K562 , Datos de Secuencia Molecular , Regiones Promotoras Genéticas , Unión Proteica , ARN Interferente Pequeño/genética , Ribonucleasa III/metabolismo , Activación Transcripcional , Células U937 , Regulación hacia Arriba
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA